Home Media/Press releases/OREGA Biotech and genOway enter a master service agreement>
Latest News
See all news

Media

Press release

OREGA Biotech and genOway enter a master service agreement

Lyon, France, July 24, 2013 – OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapies for cancer patients, announces today that it has signed a master service agreement with genOway, the biotechnology company dedicated to the development of genetically modified animal models. genOway will provide OREGA Biotech with customized mouse lines, e.g. knockout mouse models, for the validation of novel cancer targets discovered by OREGA Biotech through its Target Discovery program. The two companies started their cooperation in early 2012 with the generation of a humanized mouse model. The initiation of a new study aiming at validating the role of an undisclosed cytokine potentially involved in breast cancer progression is the kickoff of this partnership.

Download the press release. 


See all our press releases

Events
See all events